RxDoctor Payments Data

Kalyana Lavu, MD

Gastroenterology · Newburgh, INNPI 1538103759

Payments from drug & device makers

$2,866in general payments, 2019–2025

Across 160 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$594
  • Pfizer$179
  • Amgen$139
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$83
  • Regeneron Healthcare Solutions, Inc.$70
  • plus $416 from 12 others

What the payments were for

  • Food & beverage$2,77697%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,866 in reported general payments places this provider in the 50th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$116,108
Medicare patients
483
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$426,262
Skyrizi On-BodyRisankizumab-Rzaa13$261,417
Humira(Cf) PenAdalimumab11$149,860
RinvoqUpadacitinib13$131,003
XifaxanRifaximin11$36,702
Mesalamine27$25,093
CreonLipase/Protease/Amylase11$20,995
LinzessLinaclotide16$17,805
MotegrityPrucalopride Succinate13$6,766
Ursodiol14$4,047
DexilantDexlansoprazole13$3,844
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,509
SutabSod Sulf/Pot Chloride/Mag Sulf19$3,064
Omeprazole311$2,433
Azathioprine33$1,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$594$426,26214 claims
AbbVieRinvoq, Creon, Linzess$1,386$169,80440 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$83$36,70211 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$49$10,61026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →